Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/kjm2.12584 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Impact of Bevacizumab and miR200c on EMT and EGFR-TKI Resistance in EGFR-Mutant Lung Cancer Organoids.
Genes (Basel)
December 2024
Department of Pulmonology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Yokohama 236-0004, Japan.
: This research aims to investigate the mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in non-small-cell lung cancer (NSCLC), particularly focusing on the role of the epithelial-mesenchymal transition (EMT) within the tumor microenvironment (TME). : We employed an in vitro three-dimensional organoid model that mirrors the physiology of human lung cancer. These organoids consist of lung cancer cells harboring specific mutations, human mesenchymal stem cells, and human umbilical vein endothelial cells.
View Article and Find Full Text PDFRevolutionizing NSCLC Treatment: Immunotherapy Strategies for EGFR-TKIs Resistance.
Clin Respir J
December 2024
Qingdao Hiser Hospital Affiliated of Qingdao University (Qingdao Traditional Chinese Medicine Hospital), Qingdao, Shandong, China.
Article Synopsis
- Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the main treatment for advanced non-small cell lung cancer (NSCLC) patients with specific EGFR mutations, but resistance to these drugs often develops.
- Research is focusing on understanding the mechanisms behind this drug resistance and finding alternative treatment options.
- Immune checkpoint inhibitors (ICIs) are emerging as a new treatment option for late-stage NSCLC patients who have developed resistance to EGFR-TKIs, with studies investigating their effectiveness alone or in combination with other therapies.
[More Personalized Treatment using Diversified Molecular Targeted Therapy Strategies for EGFR Mutation-Positive Non-Small-Cell Lung Cancer-Sequential Treatment Comprising First- and Second-Line Therapy with EGFR-TKIs and Treatment Options in Combination with Anti-Angiogenic Agents].
Gan To Kagaku Ryoho
October 2024
Division of Medical Oncology, Dept. of Internal Medicine, Teikyo University School of Medicine.
Article Synopsis
- EGFR-TKIs are crucial for treating advanced non-small-cell lung cancer with EGFR gene mutations, with five variants approved in Japan, including gefitinib, erlotinib, afatinib, dacomitinib, and osimertinib.
- Osimertinib is the only EGFR-TKI approved for second-line therapy in patients with the T790M mutation after initial treatment, making it essential to choose the right first-line therapy carefully.
- The article presents clinical data on EGFR-TKIs for first and second-line treatments, highlights the importance of patient and mutation subtype considerations, and shares experiences from transitioning between these therapies.
Benmelstobart plus anlotinib in patients with EGFR-positive advanced NSCLC after failure of EGFR TKIs therapy: a phase I/II study.
Signal Transduct Target Ther
October 2024
Department of Medical Oncology, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.
The effect of immune-based therapies on patients with epidermal growth factor receptor (EGFR)-positive advanced non-small cell lung cancer (NSCLC) resistant to EGFR tyrosine kinase inhibitor (TKI) therapy remains unclear. The ALTER-L038 study aimed to evaluate efficacy and safety of a chemotherapy-free combination of benmelstobart, an anti-programmed cell death ligand 1 antibody, and anlotinib, a small-molecule multi-target anti-angiogenic TKI, in EGFR-positive advanced NSCLC patients who progressed after EGFR TKI therapy. Patients were enrolled in a phase I/II study.
View Article and Find Full Text PDFLong-term progression-free survival in non-small cell lung cancer patients: a spotlight on bevacizumab and its biosimilars.
Expert Opin Biol Ther
October 2024
Department of Lung Diseases Jordanovac, University Hospital Centre Zagreb, Zagreb, Croatia.
Article Synopsis
- - The study examines the evolving role of bevacizumab in treating non-small cell lung cancer (NSCLC), especially as newer immunotherapy options become more popular.
- - A thorough literature search was conducted to analyze the benefits and drawbacks of bevacizumab use in combination with other treatments, particularly in patients with central nervous system (CNS) metastases.
- - Despite bevacizumab's historical significance as a breakthrough therapy in NSCLC, recent findings focus mainly on its use with patients having specific mutations, highlighting the need for further research to clarify its current position in treatment protocols.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!